ArticleBMC medicine2026
Targeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting hepatocellular carcinoma development in mice.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatohepatitis (MASH) is a major precursor of hepatocellular carcinoma (HCC), yet the molecular mechanisms linking steatohepatitis to malignancy remain poorly defined. The STE20-type kinase MST3 associates with hepatocellular lipid droplets and regulates metabolic homeostasis and stress responses in the liver. Here, we investigated whether pharmacologic inhibition of MST3 could attenuate the initiation and progression of MASH-associated HCC in vivo.
methodsThe therapeutic potential of MST3 inhibition was evaluated in a mouse model in which MASH-HCC was induced by a single diethylnitrosamine injection followed by 30 weeks of Western-style diet feeding. Liver tumor burden was assessed after 12, 21, or 30 weeks of treatment with Mst3-targeting antisense oligonucleotide (ASO) or a non-targeting control ASO, and histological, biochemical, and mechanistic analyses were performed in the 30-week cohort. In parallel, proteomic profiling of CRISPR/Cas9-generated MST3 knockout and wild-type Huh7 cells was conducted to gain molecular insight into MST3-regulated pathways.
resultsMst3 ASO therapy had no impact on the onset or aggravation of experimentally induced MASH-associated HCC in mice, despite markedly improving the whole-body metabolic profile and suppressing all key features of MASH. Proteomic profiling of MST3-deficient hepatocytes revealed coordinated activation of mitochondrial and lysosomal pathways, consistent with enhanced fatty acid degradation and catabolic clearance.
conclusionsOur findings in the selected mouse model of MASH-HCC suggest that MST3 is dispensable for hepatocarcinogenesis, yet its antagonism dampens diet-induced metabolic dysfunction and effectively attenuates MASH severity, challenging the prevailing assumption that targeting MASH driver genes alone is sufficient to prevent HCC development in the context of obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.